Robert Morris
Robert Morris's Latest Posts
BST Trade Alert – April 9, 2015
Recommendation: Buy Verastem $NASD: VSTM up to $12.00 per share. About the Company: Verastem is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling […]
BST Position Update – April 1, 2015
. . . . Dyax (NASDAQ: DYAX) – Hold Boom! Dyax’s drug known as DX-2930, was found to have eliminated all attacks of hereditary angioedema, or HAE, when taken at doses of 300 milligrams. In others words, Dyax has found a cure for HAE. Not surprisingly, this drug is being fast tracked by the FDA. […]
BST Trade Alert – March 26, 2015
Recommendation: Buy Keryx Biopharmaceuticals $NASD: KERX up to $14.00 per share. About the Company: Keryx is a biopharmaceutical company focused on innovative therapies for the treatment of renal disease. Their product, Auryxia (ferric citrate), received marketing approval from the FDA in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, […]
BST Position Update – March 24, 2015
. . . . Merrimack Pharmaceuticals (NASDAQ: MACK) – Sell MACK hit a new high of $12.50 recently. And it’s currently trading for $11.57 per share. That’s a gain of 73% from our original buy price. And we continued to recommend accumulating shares when the stock was as low as $2.00 per share. MACK has […]
BST Trade Alert – March 13, 2015
Recommendation: Buy Kamada $KMDA up to $5.00 per share. About the Company: Kamada became the first publicly traded biopharmaceutical company based in Israel back in 2005. They specialize in plasma-derived protein therapeutics with a focus on developing specialized treatments and developing strategic partnerships. The company has done a great job of developing partnerships and generating cash […]
BST Trade Alert – February 24, 2015
Recommendation: Buy Neuralstem (AMEX: CUR) up to $4.00 per share. About the Company: Neuralstem is a clinical stage biopharmaceutical company. They focus on the development and commercialization of treatments for central nervous system diseases. Their technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous […]
BST Position Update – February 23, 2015
. . . . Array BioPharma (NASDAQ: ARRY) – Sell Our shares of ARRY have doubled in price. The most recent uptick came after the company struck a deal to purchase a cancer treatment in late stage development. There’s clearly some big upside associated with any cancer treatment. But I think the stock has gotten […]
BST Trade Alert – January 29, 2015
Recommendation: Buy Dyax (NASDAQ: DYAX) up to $16.50 per share. About the Company: DYAX is a biopharmaceutical company that develops drugs to treat Hereditary Angioedema (HAE) and Other Plasma-Kallikrein-Mediated Disorders. And we believe DYAX has enormous potential. They have one product, ecallantide, that’s already approved by the FDA for treatment of HAE in patients 12 years […]
BST Position Update – January 16, 2015
. . . . Arena Pharmaceuticals (NASDAQ: ARNA) – Hold As I pointed out in the trade alert for Arena Pharmaceuticals, the company has a proven track record of bringing new drugs to market. And they have cash flow from the sales of BELVIQ that will help support the costs of new drug developments. One […]
